Heterogeneity in systemic availability of ondansetron and granisetron following oral administration

Drug Metabolism and Disposition

Volumn 27, Issue 1, 1999, Pages 110-112

  Corrigan, B W ^a   Nicholls, B ^a   Thakrar, B ^c   Lam, R ^a   Grosse, C ^b   Alianti, J ^b   Palmer, J L ^c  

^a Glaxo Wellcome Inc   (Canada)

^b GLAXOSMITHKLINE   (United States)

^c GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CIGARETTE SMOKE; CYTOCHROME P450; GRANISETRON; ONDANSETRON;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG METABOLISM; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; MASS SPECTROMETRY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

STAPHYLOCOCCUS PHAGE 3A;

EID: 0033047283     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. 3, antagonist, in healthy human subjects. Eur J Clin Pharmacol 46:159-162.
2. 3, antagonist in young and elderly volunteers. Eur J Clin Pharmacol 48:519-520.
3. Bloomer JC, Baldwin SJ, Smith GJ, Ayrton AD, Clarke SE and Chenery RJ (1994) Characterisation of the cytochrome P450 enzymes involved in the in vitro metabolism of granisetron. Br J Clin Pharmacol 38:557-566.
4. Bower P (1995) A pharmacologic profile of oral granisetron (Kytril Tablets). Semin Oncol 22 (Suppl 10):3-5.
5. 3 receptor antagonist: Correlation with anti-emetic response. Cancer Chemother Pharmacol 24:45-49.
6. Cupissol D, Bressollle F, Adenis L, Carmichael J, Bessell E, Allen A, Wargenau M and Romain D (1993) Evaluation of the bioequivalence of tablet and capsule formulations of granisetron in patients undergoing cytotoxic chemotherapy for malignant disease. J Pharm Sci 82:1281-1284.
7. Darbar D, Dell'Orto S, Moike K, Wilkinson GR and Roden DM (1997) Dietary salt increases first pass elimination of oral quinidine. Clin Pharmacol Ther 61:292-300.
8. Dixon CM, Colthup PV, Serabjit-Singh CJ, Kerr BM, Boehlert CC, Park GR and Tarbit MH (1995) Multiple forms of cytochrome P-450 are involved in the metabolism of ondansetron in humans. Drug Metab Dispos 23:1225-1230.
9. Frye R, Bertz R, Granneman J, Qian J, Lamm J, Dennis S and Valdes J (1997) Effect of ritonivir on the pharmacokinetics and pharmacodynamics of alprazolam. Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, A-59, 12.
10. Haberer LJ and Palmer JL (1995) Evaluation of the exposure-response relationship for ondansetron in pediatric cancer patients (Abstract). Clin Pharmacol Ther 57:156.
11. Hossain M, Wright E, Baweja R, Ludden T and Miller R (1997) Nonlinear mixed effects modeling of single dose and multiple dose data for an immediate release (IR) and a controlled release (CR) dosage form of alprazolam. Pharm Res (NY) 14:309-315.
12. Kolars JC, Lown KS, Schmiedlin RP, Ghosh M, Fang C, Wrighton SA, Merion RM and Watkins PB (1994) CYP3A gene expression in human gut epithelium. Pharmacogenetics 4:247-259.
13. Lown KS, Kolars JC, Thummel KE, Barnett JL, Kunze KL and Watkins PB (1994) Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the crythromycin test. Drug Metab Dispos 22:947-955.
14. Plosker GL and Goa KL (1991) Granisetron: A review of its pharmacological properties and therapeutic use as an antiemetic. Drugs 42:805-824.
15. Pritchard JF, Bryson JC, Kernodle AE, Benedetti TL and Powell JR (1992) Age and gender effects on ondansetron pharmacokinetics: Evaluation of healthy aged volunteers. Clin Pharmacol Ther 51:51-55.
16. Pritchard JF (1995) Ondansetron metabolism and pharmacokinetics. Semin Oncol 19 (Suppl 10):9-15.
17. Roila F and Del Favero A (1995) Ondansetron clinical pharmacokinetics. Clin Pharmacokinet 29:95-109.
18. Wanwimolruk S, Wong SM, Zhang H, Coville PF and Walker RJ (1995) Metabolism of quinine in man: Identification of a major metabolite, and effects of smoking and rifampicin pretreatment. J Pharm Pharmacol 47:957-963.